Gene expression profile of acute myeloid leukemia.
Bone marrow (BM) samples from 43 adult patients with newly de novo diagnosed AML.All samples contained more than 80% blast cells. Total RNA was extracted using Trizol reagent (Life Technologies, Gaithersburg, MD) and purified with RNeasy Mini Kit (Quiagen, Valencia, CA). The RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA). The labeled RNA was then fragmented and hybridazed to HU-133A oligonucleotide array (Affymetrix, Santa Clara, CA), which contained 22,283 probe sets, according to Affymetrix protocols. The arrays were scanned using Gene Array Scanner (Affymetrix). Keywords = expression profile Keywords = myeloid leukemia Keywords = microarrays Keywords: other
Table 1. Clinical and biological characteristics of the 43 AML patients included in this study. header descriptions
Patient No.
Age/Sex
FAB/WHO
FAB/WHO classification: M3/Acute promyelocytic leukemia (APL) with t(15;17); M4Eo/Acute myeloid leukemia (AML) with abnormal bone marrow eosinophils and inv(16); M0/AML, minimally differentiated; M1/AML without maturation; M2/AML with maturation; M4/Acute myelomonocytic leukemia; M5/Acute monoblastic/monocytic leukemia; M6/Acute erythroid leukemia.
Karyotype
^c FISH analysis and RT-PCR demonstrated CBFB-MYH11 gene fusion
FISH studies
All cases except APL and AMLEo were analysed with a specific probe for MLL and those cases with unsuccessful karyotype were studied with a centromeric probe for chromosome 7.
FLT3 mutation
FLT3 mutation: ++, ITD; +, D835 mutation; ND, not done